Jenene Roberts

  • She / Her / Hers

Partner

Print Options

Jenene Roberts

Select the sections which you would like to include in the PDF:

vCard

Overview

Jenene Roberts is a partner in the Litigation and Dispute Resolution Group at Goodmans.

Jenene practises in the area of intellectual property litigation. With a particular focus on patent litigation, Jenene has significant experience and expertise in litigating cases in the pharmaceutical industry. She also appears regularly before the Federal Court of Canada in complex patent litigation, and has appeared before the Federal Court of Appeal.

Jenene is also a registered trademark agent. She has been involved in trademark opposition proceedings and expungement proceedings, having appeared before the Trademarks Opposition Board.

Prior to law school, Jenene worked as a research assistant for three years as an undergraduate chemistry student at Memorial University of Newfoundland, where she was also a recipient of numerous awards, including The Captain Robert A. Bartlett Science Award as the top undergraduate student graduating from the Faculty of Science.

Jenene was a member of the firm’s Litigation and Dispute Resolution group from 2011 – 2021 and rejoined Goodmans in 2022.

Jenene is recognized as a “Future Star” by Benchmark Litigation Canada, as "Up and Coming" by Chambers Canada, “One to Watch” by Best Lawyers in Canada, and as a “Rising Star” by IP Stars. She is also recommended by The Legal 500 Canada, The Canadian Legal Lexpert Directory and IAM Patent 1000, and is featured in the Lexpert Special Edition: Technology and Health Sciences.

Featured Work

Jenene’s representative work includes acting for:
  • Takeda Canada v Apotex, 2024 FC 106 - Counsel to Apotex in the successful dismissal of a patent proceeding relating to the drug dexlansoprazole (used to treat heartburn), on the basis of invalidity and non-infringement.
  • AbbVie Corporation v JAMP Pharma Corporation, 2023 FC 1520 - Counsel to JAMP in successfully opposing action for permanent injunction in respect of six asserted patents relating to the drug adalimumab (used to treat autoimmune disorders).
  • Janssen v Apotex, 2021 FC 7, aff’d 2022 FCA 184 - Counsel to Apotex (trial and appeal) in the successful dismissal of a patent proceeding relating to the drug abiraterone (used to treat prostate cancer), on the basis of obviousness.
  • Eli Lilly Canada v Apotex, 2018 FC 736 - Counsel to Apotex in the successful dismissal of a patent proceeding relating to the drug prasugrel (used to prevent blood clots), on the basis of obviousness.
  • Bristol-Myers Squibb Canada v Apotex, 2017 FC 1061 - Counsel to Apotex in the successful motion for summary dismissal of patent proceedings relating to the drug aripiprazole (used to treat schizophrenia), on the basis of non-infringement.
  • Valeant Canada LP v Apotex, 2016 FC 1359 - Counsel to Apotex in the successful motion for summary dismissal of patent proceedings relating to the drug metformin (used to treat diabetes), on the basis of non-infringement.
  • Takeda Canada v Canada (Health), 2015 FC 570 - Counsel to Apotex in the successful dismissal of a patent proceeding in respect of three patents relating to the drug ciclesonide (used in a nasal spray used to treat allergic rhinitis), on the basis of obviousness.
  • Teva Canada Innovation v Apotex, 2014 FC 1070 - Counsel to Apotex in the successful dismissal of a patent proceeding relating to the drug rasagiline (used to treat Parkinson’s disease), on the basis of non-infringement.
  • City of Hamilton Judicial Inquiry - Counsel to the City of Hamilton in a Judicial Inquiry into the Red Hill Valley Parkway (prior to re-joining Goodmans). 

Credentials

Professional Affiliations

  • Law Society of Ontario
  • Canadian Bar Association
  • The Advocates’ Society
  • Intellectual Property Institute of Canada – Patent Committee (2021-present)